Cheque Drops

Mibolerone — Cheque Drops by Dragon Pharma

Cheque Drops is Dragon Pharma's formulation of oral Mibolerone at 250mcg per tablet — one of the most androgenically potent compounds ever developed, used exclusively for acute pre-competition or pre-workout aggression and strength enhancement in very short windows. With an androgenic ratio approximately 41× that of testosterone, Mibolerone is not a cycle compound — it is a targeted performance tool with a maximum safe window measured in days, not weeks.

Also searched as: Mibolerone 250mcg, Cheque Drops tabs, Mibolerone pre-workout, Cheque Drops Dragon Pharma.

The Origin of "Cheque Drops" — Veterinary History

Mibolerone's history is unique among performance-enhancing compounds and represents a genuine information gap in competitor content:

• Mibolerone was developed by Upjohn Pharmaceuticals in the 1960s and approved by the FDA in 1969 — not for human use, but as a veterinary medication under the trade name "Cheque Drops"
• Its veterinary purpose: administered to female dogs to suppress estrus (heat) — "Cheque" as in "check/suppress the heat cycle"
• The compound found its way into human performance circles in the 1970s-80s, primarily among powerlifters and strength athletes seeking acute aggression enhancement immediately before competition
• This veterinary origin is why Mibolerone was never developed with human dosing studies — all human data is observational, and the compound carries particular uncertainty about long-term effects compared to AAS developed for human clinical use

Structural Relationship to Trenbolone — Why Mibolerone Is So Potent

Mibolerone's extreme potency is not coincidental — it shares structural features with Trenbolone:

• Both Mibolerone and Trenbolone are 19-nor steroids — the 19-nor modification (removal of the methyl group at C-19) significantly enhances binding to androgen receptors
• Mibolerone is additionally 7-alpha-methylated and 17-alpha-methylated — the 7-alpha methyl group further increases androgen receptor binding affinity and resistance to metabolism
• The combined effect of the 19-nor structure + 7-alpha methylation produces an androgenic ratio of approximately 4,100 (vs testosterone's 100) — more than 41× more androgenic per milligram
• This structural similarity to Trenbolone explains why Mibolerone shares many of Trenbolone's characteristic effects — aggression enhancement, extreme strength, no aromatisation — but at a scale that makes even Trenbolone seem moderate by comparison

Why Mibolerone Is Used ONLY Pre-Workout — Not as a Cycle Compound

This is the most critical and least explained aspect of Mibolerone use:

• Mibolerone is among the most hepatotoxic compounds available — significantly more so than Oral Tren (Methyltrienolone) or Superdrol. The original Upjohn veterinary research documented severe liver pathology in dogs at extended doses
• The maximum safe human exposure window is typically cited at no more than 2 weeks total cumulative use — many users limit this further to competition days only
• Its ~4-hour half-life and acute aggression effect make it uniquely suited to the pre-workout/pre-competition use case: dose 1-2 hours before an event, peak effect aligns with performance demand, cleared within 8-12 hours
• Unlike any other AAS in the Dragon Pharma range, Mibolerone is not intended to build mass or be used for multi-week anabolic benefit — it is a neurological and strength-acuity compound for acute performance windows

Effects and Benefits

• Rapid, acute increase in aggression and competitive drive — typically noticeable within 30-60 minutes of dosing
• Significant strength increases in acute performance windows — primarily neurological rather than structural
• No aromatisation — no estrogenic effects
• Short half-life (~4 hours) allows targeted use around specific performance events
• Historically used in powerlifting and strength sports for competition-day performance

Dosage and Administration

The 250mcg tablet represents a full standard dose for most users. Some advanced users take 500mcg (2 tabs) pre-competition, though side effects scale significantly. The total cumulative use window should not exceed 2 weeks — and many experienced users restrict use to competition or testing days only, with weeks or months between uses. Mibolerone is not appropriate for consecutive daily use across a standard cycle.